Publication date: October 2026 Source: European Urology Focus, Volume 12, Issue 5 Author(s): Bastiaan M. Privé, Daniela E. Oprea-Lager, Constantijn H.J. Muselaers, Bart Timmermans, Inge M. van Oort, Niven Mehra, J.P. Michiel Sedelaar, Alexis Vrachimis, Walter Noordzij, James Nagarajah
Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update. // European Urology Focus. – URL: https://www.sciencedirect.com/science/article/pii/S2405456926001665?dgcid=rss_sd_all
Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update. European Urology Focus. https://www.sciencedirect.com/science/article/pii/S2405456926001665?dgcid=rss_sd_all
“Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update.” European Urology Focus.
@article{article93800,
title = {Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update},
journal = {European Urology Focus},
url = {https://www.sciencedirect.com/science/article/pii/S2405456926001665?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...